



Aug 21, 2019

Quantitative fluorescent polymerase chain reaction (QF-PCR) for the rapid prenatal diagnosis of common fetal aneuploidies V.1 👄

PLOS One

Predrag Noveski¹, Marija Terzic¹, Marija Vujovic¹, Maja Kuzmanovska¹, Emilija Sukarova Stefanovska¹, Dijana Plaseska-Karanfilska¹

¹Research Center for Genetic Engineering and Biotechnology "Georgi D. Efremov", Macedonian Academy of Science and Arts, Skopje, Republic of Macedonia



dx.doi.org/10.17504/protocols.io.2v9ge96



Predrag Noveski



ABSTRACT

Quantitative fluorescent polymerase chain reaction (QF-PCR) is reliable and efficient method for the rapid prenatal diagnosis of common fetal aneuploidies. In this protocol we first describe a procedure for isolation of DNA from amniocytes and chorionic villi with the use of commercial kit intended for the isolation of nucleic acids from viruses, which, taking into account the phenomenon of increased fragmentation of the DNA material of fetal origin, proved to be appropriate for prenatal diagnosis. (Section 1). As part of the isolation procedure, we also include a procedure for treating amniotic fluid with visible contamination (blood with possible origin from the mother). The presented procedure consists of simple physical separation of the maternal blood cells from the fetal material in order to reduce the failure rate due to maternal cell contamination.

In the second part of the protocol (Section 2) we are presenting procedure for performing the QF-PCR analysis. Here, we describe an in-house one-tube multiplex QF-PCR method including 20 PCR markers (15 STR markers and 5 fixed size) for rapid prenatal diagnosis of chromosome 13, 18, 21, X and Y aneuploidies, which targeted in total 26 genomic positions. Of them, three markers (D13S258, D13S305 and D13S1817) were for analysis of the aneuploidies for the chromosome 13, four (D18S386, D18S390, D18S391 and D18S535) for the chromosome 18, four (D21S1411, D21S1414, D21S1435 and D21S1446) for the chromosome 21 and six for the analysis of the sex chromosome aneuploidies. Two of the sex chromosome markers (DXS6803 and XHPRT) amplified sequences only on chromosome X (for counting chromosome X), two (AMELX/Y and DXYS218) co-amplified sequences of both X and Y chromosomes (for counting chromosomes X and Y in male samples and chromosome X in female samples), one (TAF9B) was for coamplification of sequences on chromosomes X and 3 (for counting chromosome X) and one (SRY) located on chromosome Y was for male sex determination. Three remaining markers (MYPT2/Y, DYS448 and CDY1/2) were used simultaneously for detection of the Y chromosome aneuploidies and microaberrations in the azoospermia factor region "c" (AZFc), located on the Y chromosome.

For the cases with inconclusive results, we used additional QF-PCR reactions specific for given chromosome (Section 3). For chromosomes 13, 18 and 21 the primers were combined in one multiplex reaction each: four STR markers for chromosome 13 (D13S742, D13S628, D13S634 and D13S631), three STR markers for chromosome 18 (D18S51, D18S1367 and D18S978) and four STR markers for chromosome 21 (D21S1437, D21S11, D21S1412 and D21S1441). For the sex chromosomes we have used three markers as separate PCR reactions (for DXS6809, DXS996 and X22) and additionaly if needed, previously published multiplex reaction [File 1] for detection of sex chromosome aneuploidies in infertile patients.

EXTERNAL LINK

https://doi.org/10.1371/journal.pone.0221227



MATERIALS

NAME AmpliTaq Gold™ 360 DNA Polymerase CATALOG #

VENDOR

Thermo Fisher Scientific



4398823

NAME V	CATALOG #	VENDOR V	
GeneScan™ 500 LIZ™ dye Size Standard	4322682	Thermo Fisher Scientific	
Hi-Di™ Formamide	4311320	Thermo Fisher Scientific	
High Pure Viral Nucleic Acid Kit	11858874001	Roche	
5' Labeled Primers	450056	Thermo Fisher Scientific	

1 Perfom one-hour DNA isolation protocol using the commercial High Pure Viral Nucleic Acid kit (Roche Applied Science, Mannheim, Germany):

Prepare the material for isolation:

- 1. For amniotic fluid -> in a 1.5 ml tube collect amniotic fluid, centrifuge 13000 x g for 5 minutes and remove the supernatant; repeat the procedure several times (depends on the amount of amniocytes and/or volume of amniotic fluid); after the last spinning, apart from the precipitate, also retain 200 ul supernatant; vortex and proceede with isolation according to the manufacturer's protocol.
- 2. For chorionic villi -> in a 1.5 ml tube collect one or several chorionic villi and add up to 1.5 ml of 1x PBS buffer (137 mM NaCl, 10 mM phosphate, 2.7 mM KCl; pH 7.4), centrifuge at 13,000 x g for 5 minutes and remove the supernatant; repeat the procedure one more time, discard the supernatant, add 200 µl 1x PBS and proceeded with isolation according to the manufacturer's protocol.
- 3. For blood -> proceeded with isolation according to the manufacturer's protocol.

Perform isolation with High Pure Viral Nucleic Acid kit according to the following procedure:

- Add 200 μl Binding buffer
- Add 50 μl Proteinase K solution (supplied as apart of the kit); mix immediately.
- Incubate for 10 min at +72°C.
- Add 100 μl Binding Buffer and mix well.
- To transfer the sample to a High Pure Filter Tube:
- Insert one High Pure Filter Tube into one Collection Tube.
- Pipet the entire sample into the upper reservoir of the Filter Tube.
- Insert the entire High Pure Filter Tube assembly into a standard table-top centrifuge.
- Centrifuge 1 min at 8,000 × g.
- After centrifugation:
- Remove the Filter Tube from the Collection Tube; discard the flowthrough and the Collection Tube.
- · Combine the Filter Tube with a new Collection Tube.
- After combining the Filter Tube with a new Collection Tube:
- · Add 500 µl Inhibitor Removal Buffer (previosly prepared according to manufactutrer's description) to the upper reservoir of the Filter Tube.
- Centrifuge 1 min at 8,000 × g.
- After centrifugation:
- Remove the Filter Tube from the Collection Tube; discard the flowthrough and the Collection Tube.
- Combine the Filter Tube with a new Collection Tube.
- After removal of inhibitors:
- Add 450 µl Wash Buffer (previosly prepared according to manufactutrer's description) to the upper reservoir of the Filter Tube.
- Centrifuge 1 min at 8,000 × g and discard the flowthrough.
- After the first wash and centrifugation:
- Remove the Filter Tube from the Collection Tube; discard the flowthrough and the Collection Tube.
- Combine the Filter Tube with a new Collection Tube
- \bullet Add 450 μ l Wash Buffer to the upper reservoir of the Filter Tube.
- Centrifuge 1 min at 8,000 × g and discard the flowthrough. Leave the Filter Tube-Collection Tube assembly in the centrifuge and spin it for 10 s at maximum speed (approx. 13,000 × g) to remove any residual Wash Buffer.

The extra centrifugation time ensures removal of residual Wash Buffer.

- Discard the Collection Tube and insert the Filter Tube into a nuclease-free, sterile 1.5 ml microcentrifuge tube.
- To elute the nucleic acid:
- Add 30 µl for amniocytes or 50 µl (chorionic villi or blood) of Elution Buffer to the upper reservoir of the Filter Tube.
- Centrifuge the tube assembly for 1 min at 8,000 × g.
- Dissolve the pelleted DNA with the pipetor and leave at 37 °C for one hour.
- Measure the DNA concentration and proceed to the QF-PCR reaction step.


1.1 Treatment of maternal cell contamination in amniotic fluids

In order to improve the outcome of the analysis of amniotic fluids defined as samples with maternal cell contamination (MCC), perform physical separation of the potentially contaminating material:

- 1. Store the syringe with the amniotic fluid on +4°C for 6-12 hours in order to precipitate (precipitation could also be performed over night);
- 2. After separation of the two clearly visible phases, firstly collect the upper clear phase in a 1.5 ml tube without dissolving the lower phase; centrifuge at 11,000 x g for 5 minutes and discard the supernatant; repeat until all of the upper clear phase is collected, and after last centrifugation retain 200 ul supernatant;
- 3. After that, collect the lower phase separately in a new 1.5 ml tube; centrifuge at 11,000 x g for 5 minutes and discard the supernatant, but retain 200 ul supernatant;
- 4. After centrifugation of the collected amniotic fluid, perform separate isolation (as previously described) and QF-PCR analysis for the two colected pellets .

Visualisation of the procedure for the treatment of maternal cell contamination in amniotic fluids is shown in the following figure:





B)




Illustration of the treatment of the contaminated amniotic fluids. Contaminated amniotic fluid is precipitated for 6-12 hours and then A) Upper clear phase (green color) was collected resulting in amplification of a pure uncontaminated profile of the fetus and B) Afterwards, lower contaminated phase (blue color) was collected separately wherein the amplification showed maternal cell contamination. Blue circles show the contaminating alleles from the mother.

2

This section describes the main QF-PCR reaction and consists of the following steps:

- 2.1) Prepare QF-PCR multiplex primer mix;
- 2.2) Perform PCR reaction;
- 2.3) Capillary electrophoresis of the PCR product and analysis of the results.
- $2.1\,$ QF-PCR primer mix is prepared in a total volume of 200 $\mu l.$

Sequences of the primers, their GC percentages, melting points and amount of each primer used in preparation of the QF-PCR mix are shown in the following table:

Name	STR or fixed size (fs)	Sequence 5`-> 3`	GC %	Tm 0C	Amount (in µl) used in the primer mix from 50 pmol/µl of Forward/Rever se primer stocks	Concentration in the QF-PCR mix (nM)	Final concentration in the QF-PCR reaction (nM)
AMEL-X/Y-F	fs	6-FAM-CCC TGG GCT CTG TAA AGA ATA GTG	50	61	2	500	50
AMEL-X/Y-R		ATC AGA GCT TAA ACT GGG AAG CTG	46	62			
DXS6803-F	STR	VIC-GAA ATG TGC TTT GAC AGG AA	40	55	15	3750	375
DXS6803-R		CAA AAA GGG ACA TAT GCT ACT T	36	55			
DXYS218-F	STR	PET-AAT CTG GGC CTG AAG CAT TT	45	58	10	2500	250
DXYS218-R		AAG AGC GAA ACT CCG TCT CA	50	60			
TAF9B-F	fs	6-FAM-TTT GAC AGG TAG TTT TGG GTC A	41	58	3	750	75
TAF9B-R1		TGG TTT TGC CTA GGT CCA GT	50	60			
XHPRT-F	STR	6-FAM-ATG CCA CAG ATA ATA CAC ATC CCC	46	61	7	1750	175
XHPRT-R		CTC TCC AGA ATA GTT AGA TGT AGG	42	56			
D13S258-F	STR	NED-ACC TGC CAA ATT TTA CCA GG	45	57	8	2000	200
D13S258-R		GAC AGA GAG AGG GAA TAA ACC	48	56			
D13S305-F	STR	PET-AAC TAA TGC AAG GAA ATT TGT GG	35	57	12	3000	300
D13S305-R		TGA GGA CCT GTC GTT ACG AAT	48	59			
D13S1817-F	STR	6-FAM-ACC GGA CCT CAG ATC TGA AT	50	58	20	5000	500
D13S1817-R		TGC CTG AGT AAA GGA AGT GG	50	58			
D18S386-F	STR	NED-TCA GGA GAA TCA CTT GGA AC	45	55	10	2500	250
D18S386-R		TCC ATG AAG TAG CTA AGC AG	45	55			
D18S390-F	STR	VIC-GCC CAG GAT GAG GAG GTA AT	55	59	6	1500	150
D18S390-R		TCC TGG TCT GAG GTG TCA TT	50	59			
D18S391-F	STR	VIC-TGG ACT TAC CAC AGG CAA TG	50	58	5	1250	125
D18S391-R		TTC ACT ATT CCC ATC TGA GTC AC	44	58			
D18S535-F	STR	NED-AGA CAG AAA TAT AGA TGA GAA TGC A	32	57	8	2000	200
D18S535-R		TCA TGT GAC AAA AGC CAC AC	45	57			
D21S1411-F	STR	VIC-ATG ATG AAT GCA TAG ATG GAT G	36	55	10	2500	250
D21S1411-R		AAT GTG TGT CCT TCC AGG C	53	58			
D21S1414-F	STR	6-FAM-AAA TTA GTG TCT GGC ACC CAG TA	44	60	12	3000	300
D21S1414-R		CAA TTC CCC AAG TGA ATT GCC TTC	46	61			
D21S1435-F	STR	PET-CCC TCT CAA TTG TTT GTC TAC C	45	57	13	3250	325
D21S1435-R		GCA AGA GAT TTC AGT GCC AT	45	57			
D21S1446-F	STR	PET-ATG TAC GAT ACG TAA TAC TTG ACA A	32	57	12	3000	300
D21S1446-R		GTC CCA AAG GAC CTG CTC	61	58			
SRY-F	fs	6-FAM-CGG AGA AGC TCT TCC TTC CT	55	59	6,5	1625	162,5
SRY-R		TAA GTG GCC TAG CTG GTG CT	55	62			

MYPT2/Y-F	fs	6-FAM-CTC ACT ACA TGA CAT TCA GG	45	54	5	1250	125
MYPT2/Y-R		GTT TCT TCC CAG TAT CTA GTA CAG TGC	45	62			
DYS448-F	STR	PET-CAA GGA TCC AAA TAA AGA ACA GAG A	36	58	10	2500	250
DYS448-R		GGT TAT TTC TTG ATT CCC TGT G	41	56			
CDY1/2-F	fs	PET-TAT TGA GAC CCT TGC ACC TG	50	58	2	500	50
CDY1/2-R		GTT TCT TGG AGT TTC CCT TCT GTC ACC	48	65			
					176,5µl+23.5µ		
					I H2O		

- Perform main QF-PCR reaction in volume of 20 μl consisting of 1X AmpliTaq Gold 360 Buffer (Applied Biosystems Inc), 1.875 mM MgCl2, 187.5 μM each of the four dNTPs (dATP, dCTP, dGTP, and dTTP), 1.5 μl 360 GC Enhancer (Applied Biosystems Inc), 50-667 nM primers (Table 1), 0.75 U AmpliTaq Gold 360 DNA Polymerase (Applied Biosystems Inc) and 10-50 ng DNA (variable amount of DNA concentration with a minimum of 2 ng/μl for successful multiplex PCR).
 - Mix for each sample:

H2O	6,30 µl
10x PCR Buffer	$2\mu l$
25 mM MgCl2	1,5 µl
2.5mM dNTP	1,5 µl
GC rich enchancer	1,5 µl
PCR primer mix	$2 \mu l$
Taq Gold 360 DNA polymerase (5U/μL)	0,2 μΙ
DNA + H2O(if if required)	5 µl
Total	20 µl

• Thermal cycling conditions:

- Initial denaturation 95°C 10'

x 29 cycles

 - Denaturation
 95° C 45"

 - Annealing
 58° C 1'

 - Extension
 72° C 1'30"

- Final Extension 60 °C 30'
 - Final hold 4 °C

- Perform PCR reaction in Thermal Cycler ("AB 2720" or "Veriti 96 well" Thermal Cyclers in our case).
- 2.3 Capillary electrophoresis of the PCR products is performed on ABI Genetic Analyzers, in our case with ABI 3500 and ABI 3130. The procedure for preparation of the sample for capillary electrophoresis is same for both instruments:
 - Combine 1 µl of the finished PCR reaction with 12 µl of Hi-Di Formamide and 0.15 µl of GeneScan 500 LIZ Size Standard;
 - Denature on 95°C for 10' and place on ice;
 - Run on ABI Genetic analyzer for automatic capillary electrophoresis and analyze with GeneMapper analysis software according to manufacturer's protocol.

Technical specifications for running the automatic capillary electrophoresis on the ABI 3500 Genetic analyzer are:

- Polimer: POP-7;
- Capillary array: 50 cm, 8-Capillary;
- Dye Set: G5;
- Oven temperature: 60 °C;

Injection voltage: 1.6 kVolts;
PreRun voltage: 15 kvolts;
PreRun time: 180 sec.;
Injection time: 3 sec;

- Run voltage: 19.5 kvolts; - Run time: 1200 sec.

Technical specifications for running the automatic capillary electrophoresis on the ABI 3130 Genetic analyzer are:

- Polimer: POP-4;

- Capillary array: 36 cm, 4-Capillary;

- Dye Set: G5;

- Oven temperature: 60 °C;

- Injection voltage: 1.2 kVolts;

- PreRun voltage: 15 kvolts;


- PreRun time: 180 sec.;


- Injection time: 8 sec;


- Run voltage: 15 kvolts;


- Run time: 2500 sec.


Examples for electropherograms from normal male, normal female, Trisomy 21, Trisomy 18, Trisomy 13, Triploidy, Klinefelter sy., Turner sy. and Trisomy X samples are shown below:











Additional QF-PCR reactions specific for given chromosome

3

In this section, tecnical details are given about the chromosome specific backup markers. For chromosomes 13, 18 and 21, markers are combined in separate mixes, while for the sex chromosomes three markers are analyzed in single reactions.

Steps for performing QF-PCR reactions specific for given chromosome are essentially the same as main QF-PCR reaction and consists of the following steps:

- 3.1) Prepare QF-PCR multiplex primer mix / singleton mix;
- 3.2) Perform PCR reaction;
- 3.3) Capillary electrophoresis of the PCR product and analysis of the results.

3.1 QF-PCR primer mixes for chromosomes 13, 18 and 21 are prepared in a total volume of 60 µl while primers for sex chromosomes are prepared as singletons with a concentration of 10 pmol/µl of the forward+reverse primer.

Sequences of the primers, their GC percentages, melting points and amount of each primer used in preparation of the QF-PCR mix are shown in the following table:

Target chrom osome	Name	Sequence 5 '-> 3'	GC%	Tm 0C	Amount (in µI) used in the primer mix from 50 pmol/µI of Forward/Reverse primer stocks	Concentration in the QF-PCR mix (nM)	Final concentr ation in the QF-PCR reaction
Chr 13	D13S742-F	VIC-ATA ACT GGG CTA GGA ATG GAA ATA	38	60	4	3333.3	166.7
Chr 13	D13S742-R	GAC TTC CCA ATT CAG GAG GAC T	50	62.1		000010	100.7
Chr 13	D13S628-F	6-FAM-TAA CAT TCA TTG TCC CTT ACA GAT	33	58.3	12	10000.0	500.0
Chr 13	D13S628-R	GCA AGG CTA TCT AAC GAT AAT TCA	38	60.3			
Chr 13	D13S634-F	VIC-TCC AGA TAG GCA GAT TCA AT	40	54.3	16	13333.3	666.7
Chr 13	D13S634-R	CCT TCT TCT TCC CAT TGA TA	40	54.3			
			FC 04		4	2222.2	1667
Chr 13	D13S631-F	VIC-GGC AAC AAG AGC AAA ACT CT	56.84	45	4	3333.3	166.7
Chr 13	D13S631-R	TAG CCC TCA CCA TGA TTG G	56.47	52.63		16667	00.0
Chr 13	D13S258-F	NED-ACC TGC CAA ATT TTA CCA GG	45	56.8	2	1666.7	83.3
Chr 13	D13S258-R	GAC AGA GAG AGG GAA TAA ACC	47.62	55.7	00 1 00 11100		
01 40	D.10051 5	NED 010 001 TOT TO1 TO0 010 TO		10.5	= 38 µl + 22 µl H20	00000	1447
Chr 18	D18S51-F	NED-GAG CCA TGT TCA TGC CAC TG	55	60.5	4	3333.3	166.7
Chr 18	D18S51-R	CAA ACC CGA CTA CCA GCA AC	55	60.5		00000	1447
Chr 18	D18S1367-F	6-FAM-TTG GTT CAT CCA AAC ATG GT	40	54.3	4	3333.3	166.7
Chr 18	D18S1367-R	ATA ACT GCA GAG AAC GTT GC	45	56.4			
Chr 18	D18S978-F	VIC-TTC TTC AGT ATC ATC TTG TGC C	41	58.4	6	5000.0	250.0
Chr 18	D18S978-R	GCC AAATGT AGA TCT TGG GA	45	56.4			
Chr 18	D18S391-F	VIC-TGG ACT TAC CAC AGG CAA TG	50	58.4	2	1666.7	83.3
Chr 18	D18S391-R	TTC ACT ATT CCC ATC TGA GTC AC	43.5	58.2			
					= 16 µl + 44 µl H20		
Chr 21	D21S1437-F	PET-ATG TAC ATG TGT CTG GGA AGG	48	59.5	4	3333.3	166.7
Chr 21	D21S1437-R	TTC TCT ACA TAT TTA CTG CCA ACA	33	58.3			
Chr 21	D21S11-F	NED-TAT GTG AGT CAA TTC CCC AAG TGA	42	62	4	3333.3	166.7
Chr 21	D21S11-R	GTT GTA TTA GTC AAT GTT CTC CAG	38	60.3			
Chr 21	D21S1412-F	6-FAM-CGG AGG TTG CAGTGA GTT G	58	59.5	4	3333.3	166.7
Chr 21	D21S1412-R	GGG AAGGCT ATG GAG GAG A	58	59.5			
Chr 21	D21S1441-F	6-FAM-CAA AGC TGC AGT GAG CTG TA	50	58.4	4	3333.3	166.7
Chr 21	D21S1441-R	CTC AGG GAA CTG ATG GTC AC	55	60.5			
Chr 21	D21S1411-F	VIC-ATG ATG AAT GCA TAG ATG GAT G	36.4	54.8	4	3333.3	166.7
Chr 21	D21S1411-R	AAT GTG TGT CCT TCC AGG C	52.6	58.2			
					= 20 µl + 40 µl H2O		
Chr X+Y	X-22-F	6-FAM-TAA TGA GAG TTG GAA AGA AA	30	50.2	/	/	500.0
Chr X+Y	X-22-R	CCC ATT GTT GCT ACT TGA GA	45	56.4			
Chr X	DXS6809-F	VIC-TGA ACC TTC CTA GCT CAG GA	50	58.4	/	/	500.0
Chr X	DXS6809-R	TCT GGA GAA TCC AAT TTT GC	40	54.3			
Chr X	DXS996-F	VIC -AAATTCTTGCTTAGGCCACTCTAGG	44	61	/	/	500.0
Chr X	DXS996-R	GTTGTTCTGGATCGTATGCTAGG	48	59			

- Perform main QF-PCR reaction in volume of 20 µl consisting of 1X AmpliTaq Gold 360 Buffer (Applied Biosystems Inc), 1.875 mM MgCl2, 187.5 µM each of the four dNTPs (dATP, dCTP, dGTP, and dTTP), 1.5 µl 360 GC Enhancer (Applied Biosystems Inc), 83-500 nM primers (Table 1), 0.75 U AmpliTaq Gold 360 DNA Polymerase (Applied Biosystems Inc) and 10-50 ng DNA (variable amount of DNA concentration with a minimum of 2 ng/µl for successful multiplex PCR).
 - Mix for each sample:

H20	7,30 µl
10x PCR Buffer	$2 \mu l$
25 mM MgCl2	1,5 µl
2.5mM dNTP	$1,5\mu l$
GC rich enchancer	1,5 µl
PCR primer mix	1 μΙ
Taq Gold 360 DNA polymerase (5U∕µL)	0,2 μΙ
DNA + H2O(if required)	$5 \mu l$
Total	$20\mu l$

Thermal cycling conditions:

- Initial denaturation	95°C 10'

x 29 cycles

 - Denaturation
 95°C 45"

 - Annealing
 58°C 1'


 - Extension
 72°C 1'30"

Final Extension 60 °C 30'
 Final hold 4 °C

- Perform PCR reaction in Thermal Cycler ("AB 2720" or "Veriti 96 well" Thermal Cyclers in our case).
- 3.3 Capillary electrophoresis of the PCR products is performed on ABI Genetic Analyzers, in our case with ABI 3500 and ABI 3130. The procedure for preparation of the sample for capillary electrophoresis is same for both instruments:
 - Combine 1 μl of the finished PCR reaction with 12 μl of Hi-Di Formamide and 0.15 μl of GeneScan 500 LIZ Size Standard;
 - Denature on 95°C for 10' and place on ice;
 - Run on ABI Genetic analyzer for automatic capillary electrophoresis and analyze with GeneMapper analysis software according to manufacturer's protocol.

Technical specifications for running the automatic capillary electrophoresis on the ABI 3500 and ABI 3130 Genetic analyzers are same as for main QF-PCR reaction.

Examples for electropherograms from samples with Trisomy 21, Trisomy 18 and Trisomy 13 are shown below:



This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited